Synaptic Stabilizers represent a promising therapeutic approach for neurodegenerative diseases aimed at preserving synaptic structure and function. This page provides comprehensive information about synaptic stabilization mechanisms, therapeutic strategies, and current research progress. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Disease-Modifying Therapy | [4]
| Target | Synaptic Integrity | [5]
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD | [6]
| Stage | Preclinical to Phase II | [7]
Synaptic loss is a hallmark of neurodegenerative diseases and correlates strongly with cognitive decline. Synaptic stabilizers aim to prevent or reverse synaptic dysfunction by targeting proteins and pathways critical for synaptic structure, vesicle cycling, and neuronal connectivity. [8]
Synaptic stabilizers employ multiple strategies to preserve synaptic function:
| Compound | Company | Mechanism | Phase | Indication |
|---|---|---|---|---|
| Ampalactone | - | β-secretase inhibitor + synaptic protection | Preclinical | AD |
| Bryostatin | Neurotrope | PKC activator, synaptic plasticity | Phase II | AD |
Studies in AD mouse models show that synaptic stabilizers:
In PD models, synaptic stabilizers have demonstrated:
ALS research shows:
Synaptic stabilizers are being explored in combination with:
Many synaptic stabilizer candidates face challenges crossing the BBB, requiring:
Ensuring proper targeting without disrupting normal synaptic function:
Monitoring synaptic health in clinical trials:
Emerging approaches include:
The study of Synaptic Stabilizers has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Selkoe DJ. Alzheimer's disease is a synaptic failure. 2002. ↩︎
Hung CO, Coleman MP. Protecting Synapses: An Emerging Treatment Strategy for Neurodegenerative Diseases. 2016. ↩︎
Liu J, et al. Synaptic dysfunction and regeneration in neurodegenerative diseases. 2022. ↩︎
Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. 2014. ↩︎
Blennow K, et al. Synaptic pathology in Alzheimer's disease: beyond the cholinergic hypothesis. 2000. ↩︎
Dong Y, et al. Synaptic dysfunction in Alzheimer's disease: mechanisms and therapeutic strategies. 2022. ↩︎
Marsh J, et al. Synaptic stabilization as a therapeutic target in neurodegenerative disease. 2021. ↩︎
Chen X, et al. Small molecule synaptic stabilizers for neurodegenerative diseases. 2023. ↩︎